SCHEMBL763992

SCHEMBL763992

COC(=O)Cc1c[nH]c(C#N)c1-c1ccc(N)c(F)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.34
GAA P10253 1/20 0.34
GFER P55789 1/20 0.34
IKBKB O14920 1/20 0.34
CYP3A4 P08684 2/20 0.32
MAP4K1 Q92918 2/20 0.32
ABL1 P00519 1/20 0.32
CHEK1 O14757 2/20 0.32
CTSL P07711 1/20 0.32
CTSS P25774 1/20 0.32
CTSK P43235 1/20 0.32
KDM4E B2RXH2 4/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
RET P07949 2/20 0.32
DHODH Q02127 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
MAPT P10636 3/20 0.31
ICMT O60725 1/20 0.31
ACLY P53396 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10123687 0.83 PDGFRB (0.39) ALDH1A1GAACHEK1CTSKMAPT
SCHEMBL765323 0.78 ALDH1A1 (0.33) ALDH1A1GAAGFERIKBKBCTSL
SCHEMBL12909120 0.76
SCHEMBL742641 0.76 JAK3 (0.42) ALDH1A1KDM4EL3MBTL1MAPTSMN1; SMN2
SCHEMBL765513 0.74 PDGFRB (0.39) ALDH1A1GAACYP3A4CHEK1KDM4E
SCHEMBL762321 0.72
SCHEMBL5957236 0.68 ALDH1A1 (0.64) ALDH1A1GAAGFERCHEK1KDM4E
SCHEMBL30192992 0.68 ALDH1A1 (0.64) ALDH1A1GAAGFERCHEK1KDM4E
SCHEMBL10123850 0.68 FGFR1 (0.40)
SCHEMBL6072554 0.65 ALDH1A1 (0.44) ALDH1A1GAAGFERCYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338594-B2 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase BAYER HEALTHCARE LLC (US) 2012-12-25 US disclosed
US-8138336-B2 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase BAYER HEALTHCARE LLC (US) 2012-03-20 US disclosed
US-20110021518-A1 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE BAYER HEALTHCARE LLC. (US) 2011-01-27 US disclosed
US-20100273800-A1 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE BAYER HEALTHCARE LLC 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021518-A1 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE AURKC, AURKA, PLK1 ALDH1A1 3546/4885GAA 2799/4885GFER 4750/4885
US-20100273800-A1 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE AURKC, AURKA, PLK1 ALDH1A1 3546/4885GAA 2799/4885GFER 4750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.